Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Treatment Strategies for Non-Small Cell Lung Cancer with Common EGFR Mutations: A Review of the History of EGFR TKIs Approval and Emerging Data
Julian A. Marin‐Acevedo, Bruna Pellini, ErinMarie O. Kimbrough, et al.
Cancers (2023) Vol. 15, Iss. 3, pp. 629-629
Open Access | Times Cited: 23

Showing 23 citing articles:

Fusion of shallow and deep features from 18F-FDG PET/CT for predicting EGFR-sensitizing mutations in non-small cell lung cancer
Xiaohui Yao, Yuan Zhu, Zhenxing Huang, et al.
Quantitative Imaging in Medicine and Surgery (2024) Vol. 14, Iss. 8, pp. 5460-5472
Open Access | Times Cited: 26
ctDNA for the Evaluation and Management of EGFR-Mutant Non-Small Cell Lung Cancer
Aakash Desai, Tadana A. Vázquez, Keishla M. Arce, et al.
Cancers (2024) Vol. 16, Iss. 5, pp. 940-940
Open Access | Times Cited: 14
Clinical outcome analysis of different first‑ and second‑generation EGFR‑tyrosine kinase inhibitors in untreated patients with EGFR‑mutated non‑small cell lung cancer with baseline brain metastasis
Chih‐Hung Hsu, Li‐Chung Chiu, How‐Wen Ko, et al.
Oncology Letters (2025) Vol. 29, Iss. 4, pp. 1-12
Open Access | Times Cited: 1
Cetuximab-based PROteolysis targeting chimera for effectual downregulation of NSCLC with varied EGFR mutations
Richa Vartak, Bhavesh Deore, Carlos Sanhueza, et al.
International Journal of Biological Macromolecules (2023) Vol. 252, pp. 126413-126413
Open Access | Times Cited: 14
Clinical significance of TP53 alterations in advanced NSCLC patients treated with EGFR, ALK and ROS1 tyrosine kinase inhibitors: An update
Joanna Moes-Sosnowska, Adam Szpechciński, Joanna Chorostowska‐Wynimko
Tumor Biology (2023) Vol. 46, Iss. s1, pp. S309-S325
Open Access | Times Cited: 12
Recent advances in the use of liquid crystalline nanoparticles for non-small cell lung cancer treatment
Thiagarajan Madheswaran, Dinesh Kumar Chellappan, Fiona Sze Nee Lye, et al.
Expert Opinion on Drug Delivery (2025)
Closed Access
Targeted treatment and survival in advanced non-squamous non-small cell lung cancer patients – a nationwide and longitudinal study
Johanne Elise Nyen, Andrew Booth, Øyvind Husby, et al.
Frontiers in Oncology (2025) Vol. 15
Open Access
Expert consensus on the use of third-generation EGFR-TKIs in EGFR-mutated advanced non-small cell lung cancer with various T790M mutations post-resistance to first-/second-generation EGFR-TKIs
Jietao Ma, Le‐Tian Huang, Cheng‐Bo Han
Therapeutic Advances in Medical Oncology (2024) Vol. 16
Open Access | Times Cited: 3
Current status of molecular diagnostics for lung cancer
Evgeny N. Imyanitov, Elena V. Preobrazhenskaya, С. В. Орлов
Exploration of Targeted Anti-tumor Therapy (2024) Vol. 5, Iss. 3, pp. 742-765
Open Access | Times Cited: 2
Epithelial-mesenchymal transition is associated with osteopontin-induced EGFR-TKI resistance in EGFR mutant non-small cell lung cancer
Junjie Chen, Lin Shi, Qian Yao, et al.
Journal of Thoracic Disease (2023) Vol. 15, Iss. 6, pp. 3359-3371
Open Access | Times Cited: 4
Pneumonitis in Patients Receiving Thoracic Radiotherapy and Osimertinib: A Multi-Institutional Study
Leou Ismael Banla, Alice Tzeng, John P. Baillieul, et al.
JTO Clinical and Research Reports (2023) Vol. 4, Iss. 10, pp. 100559-100559
Open Access | Times Cited: 4
Response to osimertinib in a colorectal cancer patient with an EGFR T790M mutation: A case report
Blake Buzard, Lindsey Douglass, Beth Gustafson, et al.
World Journal of Gastrointestinal Oncology (2023) Vol. 15, Iss. 10, pp. 1829-1834
Open Access | Times Cited: 4
The predictive value of serum tumor markers for EGFR mutation in non-small cell lung cancer patients with non-stage IA
Wenxing Du, Tong Qiu, Hanqun Liu, et al.
Heliyon (2024) Vol. 10, Iss. 9, pp. e29605-e29605
Open Access | Times Cited: 1
Efficacy and safety of EGFR-TKIs for non-small cell lung cancer: A meta-analysis of randomized controlled clinical trials
Xiaoming Lai, Jinlin Zeng, Zhijun Xiao, et al.
Medicine (2024) Vol. 103, Iss. 23, pp. e38277-e38277
Open Access | Times Cited: 1
The relevance of the reference range for EGFR testing in non-small cell lung cancer patients
Pasquale Pisapia, Alessandro Russo, Caterina De Luca, et al.
Lung Cancer (2024) Vol. 198, pp. 108002-108002
Open Access | Times Cited: 1
The activity of a PI3K δ-sparing inhibitor, MEN1611, in non-small cell lung cancer cells with constitutive activation of the PI3K/AKT/mTOR pathway
Giuliana Papoff, Dario Presutti, Valentina Fustaino, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 2
The Role of SPEN Mutations as Predictive Biomarkers for Immunotherapy Response in Colorectal Cancer: Insights from a Retrospective Cohort Analysis
Yuanmei Dong, Sisi Ye, Huizi Li, et al.
Journal of Personalized Medicine (2024) Vol. 14, Iss. 2, pp. 131-131
Open Access
ctDNA SNORD3F Hypermethylation is a Prognostic Indicator in EGFR-TKI-Treated Advanced Non-Small Cell Lung Cancer
Bin Liu, Bingtian Zhao, Yan Yin, et al.
Cancer Management and Research (2024) Vol. Volume 16, pp. 1405-1416
Open Access
Zielgerichtete Therapie des NSCLC
Diego Kauffmann‐Guerrero, Rudolf M. Huber
InFo Hämatologie + Onkologie (2024) Vol. 27, Iss. 10, pp. 36-41
Closed Access
Construction of a Diagnostic Model for Non-IA Stage NSCLC with Rare EGFR Mutations
宏岩 张
Advances in Clinical Medicine (2024) Vol. 14, Iss. 05, pp. 1798-1806
Closed Access
Encouraging Fussy Eaters in EGFR-Mutated Lung Cancer
Steven G. Gray, Luciano Mutti, Tomer Meirson
Journal of Thoracic Oncology (2024) Vol. 19, Iss. 8, pp. 1125-1127
Closed Access
Der Biomarker EGFR in der Tumorpathologie
Ulrich Lehmann, Albrecht Stenzinger
Deleted Journal (2024) Vol. 45, Iss. 5, pp. 344-346
Closed Access
Comprehensive analysis of genomic alterations and novel prognostic biomarkers, and establishment of prediction models of metastasis in metastatic non-small cell lung cancer
Kangwei Wang, Meifeng Ye, Zexun Mo, et al.
Journal of Cancer (2024) Vol. 16, Iss. 1, pp. 339-350
Closed Access
Page 1

Scroll to top